Albert David Ltd (ALBERTDAVD) AI Stock Analysis

• Market Cap: ₹4.50B
• Dividend Yield: 0.63%
• Average Volume (3M): 270.00
• Price to Earnings (P/E): 71.5
• Beta (1Y): 0.97
• Revenue Growth: -9.14%
• EPS Growth: -91.11%
• Country: IN
• Employees: 1,497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.91
• Shares Outstanding: 5,707,162
• 10 Day Avg. Volume: 332
• 30 Day Avg. Volume: 270
• PEG Ratio: -0.36
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 1.37
• P/FCF Ratio: -10.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹808.00
• Price Target Upside: 2.49% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: ₹808.00 ▲(2.49% Upside)

Albert David Ltd's stock score is primarily impacted by its financial performance and technical analysis. The company's strong balance sheet is overshadowed by declining revenue, profitability, and negative cash flows. Technical indicators suggest bearish momentum, and the high P/E ratio indicates overvaluation. These factors contribute to a cautious outlook for the stock.

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Ltd (ALBERTDAVD) is a diversified company primarily engaged in the manufacturing and distribution of specialized medical devices and healthcare products. Operating in the healthcare sector, the company focuses on developing innovative solutions that cater to the needs of healthcare providers and patients. Its core products include diagnostic equipment, surgical instruments, and related consumables, which are designed to enhance patient outcomes and streamline healthcare operations.

How the Company Makes Money

Albert David Ltd generates revenue through multiple streams, primarily by selling its medical devices and healthcare products to hospitals, clinics, and healthcare distributors. The company engages in direct sales and also leverages partnerships with key healthcare organizations and distributors to expand its market reach. Additionally, Albert David may earn revenue through service contracts, maintenance agreements, and training programs associated with their products. The company's strategic collaborations with research institutions and healthcare providers also contribute to its earnings by facilitating product development and enhancing its market competitiveness.

Albert David Ltd Financial Statement Overview

Summary

Albert David Ltd demonstrates strength in its balance sheet with low leverage and strong equity. However, declining revenue and profitability, along with negative operating and free cash flows, are critical challenges. The company must address these issues to sustain long-term growth and financial health.

Income Statement

Albert David Ltd has shown a mixed performance in terms of revenue and profitability. The gross profit margin is strong, indicating effective cost management, but the net profit margin has declined significantly in the latest year, reflecting a decrease in profitability. Revenue has shown fluctuations, with a notable decline in the most recent year, which is a concern for growth prospects.

Balance Sheet

The company's balance sheet reflects solid equity and a low level of debt, which is a positive indicator of financial stability. The equity ratio is robust, and the company has maintained a strong return on equity, although it has decreased in the latest year. The low debt-to-equity ratio limits financial risk.

Cash Flow

Cash flow from operations has turned negative in the latest year, which is a significant drawback. Free cash flow also fell into negative territory, indicating potential liquidity issues. In previous years, cash flow metrics were healthier, but the recent downturn in free cash flow growth rate raises concerns about the company's ability to generate cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.27B	3.46B	3.60B	3.42B	3.12B	2.46B
Gross Profit	2.16B	2.29B	2.32B	2.18B	1.95B	1.58B
EBITDA	-95.32M	30.26M	1.05B	598.68M	567.76M	364.59M
Net Income	62.94M	172.01M	754.20M	361.75M	352.58M	221.43M
Balance Sheet
Total Assets	0.00	5.11B	4.98B	4.23B	4.03B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.44B	2.44B	2.85B	2.03B	1.75B	1.49B
Total Debt	0.00	123.17M	33.24M	53.18M	56.62M	16.19M
Total Liabilities	-3.92B	1.19B	1.15B	1.12B	1.23B	970.20M
Stockholders Equity	3.92B	3.92B	3.83B	3.12B	2.79B	2.44B
Cash Flow
Free Cash Flow	0.00	-432.92M	346.28M	52.78M	292.83M	349.79M
Operating Cash Flow	0.00	-284.36M	455.02M	105.15M	403.65M	366.11M
Investing Cash Flow	0.00	233.01M	-332.48M	-49.95M	-396.97M	-366.84M
Financing Cash Flow	0.00	1.10M	-82.70M	-63.62M	-12.59M	-17.05M

Albert David Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 788.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 788.4 is below the 20-day moving average (MA) of 791.56, below the 50-day MA of 800.54, and below the 200-day MA of 898.49, indicating a bearish trend. The MACD of -3.31 indicates Negative momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 47.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYKALABS	58 Neutral	₹3.37B	44.87	―	―	19.40%	1286.88%
ALBERTDAVD	55 Neutral	₹4.50B	71.49	―	0.63%	-9.14%	-91.11%
ZIMLAB	54 Neutral	₹3.36B	35.73	―	―	-3.36%	-47.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIKASLIFE	47 Neutral	₹3.92B	―	―	―	9.42%	-12220.00%
NECLIFE	43 Neutral	₹3.11B	30.02	―	―	-3.41%	-3028.44%
BROOKS	42 Neutral	₹3.64B	283.34	―	―	10.30%	―